Navigation Links
GranuFlo Recall Lawyers at Wright & Schulte LLC Investigating GranuFlo Lawsuits on Behalf of Dialysis Patients Allegedly Injured by GanuFlo or NaturaLyte
Date:8/12/2013

Columbus, OH (PRWEB) August 13, 2013

The GranuFlo recall lawyers at Wright & Schulte LLC, an experienced law firm representing the victims of defective drugs, are now evaluating GranuFlo lawsuits relating to the March 2012 GranuFlo and Naturalyte dialysis concentrate recall. GranuFlo and NaturaLyte, both manufactured and marketed by Fresenius Medical Care, were named in a Class I recall by the U.S. Food & Drug Administration (FDA). A Class I recall is the FDA’s most serious recall and is issued when a medical product poses a risk of serious injury or death.
[fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm, FDA, March 29, 2013]

Dialysis patients or their surviving family members may be eligible to file a GranuFlo lawsuit if they suffered a sudden, serious heart problem during or after a dialysis treatment that involved the administration of GranuFlo or NaturaLyte, including:

  • Heart Attack
  • Stroke
  • Cardiopulmonary Arrest
  • Dangerously Low Blood Pressure
  • Sudden Cardiac Death

Wright & Schulte LLC is offering free GranuFlo lawsuit legal consultations to individuals who may be eligible to file a GranuFlo recall claim. For more information on filing a GranuFlo lawsuit, or to arrange for a free GranuFlo lawsuit legal consultation, please visit yourlegalhelp.com.

GranuFlo and NaturaLyte are administered during dialysis to neutralize acid in the blood. According to an Urgent Product Notification issued by Fresenius Medical Care in March 2012, both drugs have the potential to cause high levels of bicarbonate in the blood, which can cause dialysis patients to experience metabolic alkalosis. Metabolic alkalosis is associated with the occurrence of sudden, serious heart problems, which can ultimately lead to death. Because of the severity of GranuFlo side effects, the FDA designated the notification a Class I recall.
[fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm, FDA, March 29, 2013]

Court filings show that more than 300 GranuFlo lawsuits have been filed in a federal multidistrict litigation that has been established in U.S. District Court, District of Massachusetts for federal personal injury claims stemming from the GranuFlo and NaturaLyte recall. The litigation’s Initial Scheduling Conference will be held on August 30, 2013. Plaintiffs in these GranuFlo lawsuits allege that Fresenius Medical Care was aware of the heart problems associated with the drugs, but concealed those risks from doctors and patients, and continued to aggressively market GranuFlo and NaturaLyte in spite of that knowledge. According to court documents, Fresenius sent a memo to its own dialysis centers in November 2011 warning that GranuFlo had been associated with an increase in incidents of cardiac arrest at Fresenius dialysis clinics in 2010. Doctors were advised to take steps to avoid elevated bicarbonate levels in patients, including adjusting dosage of the drug. However, clinics outside of the Fresenius network were not issued a similar warning until Fresenius announced its Urgent Product Notification March 2012. [In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428]

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free GranuFlo lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com

Read the full story at http://www.prweb.com/releases/2013/8/prweb10939356.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Granuflo Multidistrict Litigation Moves Forward: Now, AttorneyOne Can Provide Advice
2. GranuFlo Lawsuit News: W.Va. Man’s Lawsuit Goes to Federal Court, Rottenstein Law Group LLP Reports
3. GranuFlo Lawsuits Move Forward, as Bernstein Liebhard Notes Issuance of New Order in Federal GranuFlo Recall Litigation
4. GranuFlo Lawsuits Moving Forward in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports
5. Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama
6. GranuFlo Lawsuit News: Bernstein Liebhard LLP Reports on Growing Litigation Surrounding GranuFlo Recall
7. New Granuflo Cardiac Arrest Lawsuit: Now, AttorneyOne Can Provide Advice
8. The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
9. GranuFlo Lawsuits Filed in Wake of GranuFlo and NaturaLyte Recall Mount in State and Federal Courts, Bernstein Liebhard LLP Reports
10. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
11. GranuFlo Recall Website Launched By Hissey Kientz, LLP Law Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Farmingdale, NY (PRWEB) , ... March 27, 2017 ... ... specializing in epigenetic research products enables researchers to pursue the recent RNA methylation ... RNA methylation . In light of the newfound characteristics of N6-methyladenosine, or ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association of Healthcare ... will hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will ... chain and value analysis professionals have a ‘seat at the table’ with clinical ...
(Date:3/27/2017)... ... ... According to the American Cancer Society , the average 15-year survival ... the cancer spreads to other organs, bones, or lymph nodes, however, the 5-year survival ... latter group, tune in to Lifestyle Magazine on April 9, 2017, to ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... Conventional sodium testing methods are complicated and require expert user knowledge. In a ... analytical method dedicated to the simplified, yet highly accurate, determination of sodium. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... agreement to resolve the pending litigation between itself and 1800 Vending DBA Healthy ... Utah). , “I am thrilled to announce that we have now reached a ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing ... children, today reported financial results for the fourth ... and provided an update on its corporate activities. ... during the fourth quarter of 2016 through the ... study, and with our lead development candidate, PRX-OTC, ...
Breaking Medicine Technology: